Reverse dot blot hybridization assay— An expeditious diagnostic tool for drug resistant TB

Authors

  • Faeez Muhammad 3rd year MBBS Student, Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan
  • Laiba Siddiqui 3rd year MBBS Student, Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan
  • Rabbia Gul 3rd year MBBS Student, Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan

DOI:

https://doi.org/10.47391/JPMA.4147

Abstract

Tuberculosis (TB) is one of the leading infectious diseases that is highly transmissible. It is reported to cause approximately 10 million infections and 1.4 million deaths globally in the year of 2019.¹ Prompt detection and treatment of TB are essential to intercept the proliferation of the disease. In the case of drug- resistant TB, failure to detect the resistance of anti TB drugs may give rise to extensively drug- resistant tuberculosis (XDR-TB). Thus, the rapid detection of drug resistance is vital;, however, the current standard drug susceptibility tests (DST) may take up to 12 weeks raising an alarming concern.² A study was done in China by Li Wan et al, on the accuracy of the reverse dot blot hybridization assay (RDBH) for rapidly detecting the resistance of four anti TB drugs (rifampicin (RIF), isoniazid (INH), streptomycin (SM) and ethambutol (EMB)) in mycobacterium tuberculosis (MTB) isolates.³

Continuous...

Published

2022-01-05

Issue

Section

Letter to the Editor